Strategic agenda aiming at capitalizing Orexo’s assets

The lead product, ZUBSOLV®, is an important cash generator that has paved the way for investments in future growth drivers. The focus has been on developing new improved pharmaceuticals built on the novel drug delivery platform; amorphOX®, and to invest in an innovative product category; evidence-based digital therapies. Based on a broader foundation, the key prioritization going forward is to accelerate revenue streams, and in combination with increased cost efficiency, strengthen the financial position.

Business strategy

Sustainability strategy